• Redx to present preclinical data on RXC009 at ASN

    Read more
  • Confirmation of Directorate Change

    Read more
  • Directorate Change

    Read more
  • Zelasudil granted FDA Orphan Drug Designation

    Read more
  • Directorate Change

    Read more
  • Redx to Present at Jefferies Global Healthcare Conference in New York

    Read more
  • Interim Results for the Six Months Ended 31 March 2023

    Read more
  • Discovery of Pirtobrutinib Recognised with Plaque

    Read more
  • Redx Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models

    Read more
  • Notice of Interim Results

    Read more